ArticleNature communications2025
Interplay between T3SS effectors, ExoY activation, and cGMP signaling in Pseudomonas aeruginosa infection.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence and genotypic distribution of virulence factor genes and antibiotic susceptibility profiles in clinicalMicrobiology spectrum · 2026Article
- Comparative analysis of microbial diversity and clinical outcomes in critically ill patients with and without malignancies: a single-center retrospective cohort study.Frontiers in microbiology · 2026Article
- Comparative phenotypic and genotypic analysis of distinctFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The Type III Secretion System (T3SS) of Pseudomonas aeruginosa injects effector proteins into host cells to subvert cellular processes and promote infection. While the roles of several T3SS effectors in virulence are well established, the function of the nucleotidyl cyclase ExoY has remained elusive and debated. Here, we show that ExoY-produced cyclic GMP (cGMP) regulates the cytotoxic activity of the co-injected effector ExoT, thereby modulating host cell damage. Using engineered P. aeruginosa strains expressing ExoY variants with distinct substrate preferences, we demonstrate that cGMP production by ExoY limits ExoT-mediated dephosphorylation of the host adaptor protein CrkII, a downstream consequence of ExoT's ADP-ribosyltransferase activity. This attenuation reduces ExoT-induced cell retraction and decreases bacterial virulence. In contrast, we find that ExoT and another T3SS effector, ExoS, can inhibit ExoY activity and cGMP production in certain cell types, thus limiting ExoY's regulatory influence. These findings highlight the intricate interplay between T3SS effectors within host cells and reveal an unrecognized layer of ExoY-based complexity in P. aeruginosa's pathogenic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.